Glenmark initiates IND‐enabling studies of bispecific monoclonal antibody targeting EGFR
GBR 1372 is the third bispecific antibody and also Glenmark’s third clinical candidate targeting an oncology indication
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.